Aardvark Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing small-molecule therapies for metabolic diseases. Recent 8-K reports cover financial results, pipeline and business updates, ARD-101 HERO trial disclosures in Prader-Willi Syndrome, ARD-201 obesity program updates, clinical protocol matters, and corporate presentation materials.
The filing record also includes capital-structure disclosures tied to a shelf registration statement and equity distribution agreement, governance and executive-transition matters, compensatory arrangements, and the role of Ardia Therapeutics as a wholly owned subsidiary supporting Aardvark's dermatology pipeline.
Aardvark Therapeutics, Inc. reported exploratory efficacy data from its previously terminated Phase 3 HERO trial and open-label extension (OLE). HERO ended early after randomizing 67 of 90 planned participants, so all efficacy data are considered exploratory. At Week 2 of dose escalation, the company observed a modest reduction in HQ-CT score versus placebo; OLE participants who switched from placebo to ARD-101 had an observed average reduction of 6 points.
ARD-101 was generally well tolerated, with most adverse events mild to moderate. One cardiac serious adverse event occurred at 800 mg twice daily in a participant also taking pitolisant; the FDA concurred that the event was related to a drug-drug interaction. The FDA lifted the clinical hold on October 22, 2026. Aardvark plans to request an FDA meeting about a new Phase 3 design and expects to resume PWS clinical activities in 2027; planned dosing is at a dose below 800 mg twice daily, pending FDA discussion.
Aardvark Therapeutics, Inc. announced that the FDA lifted the clinical hold on its Investigational New Drug application for ARD-101 to treat hyperphagia in Prader-Willi syndrome. The company plans to resume clinical development after additional anticipated engagement and alignment with the FDA on the Phase 3 trial design. Aardvark had paused dosing in the Phase 3 HERO and open-label extension trials after reversible ECG changes were observed during routine monitoring in a separate healthy-volunteer study; the FDA placed the hold in May 2026.
A recently completed ECG study found no cardiac events at ARD-101 doses of 200 mg and 400 mg twice daily. Aardvark also conducted an in vitro cardiac sodium channel study. The company will host an investor webcast on October 23, 2026, at 8:00 a.m. ET to discuss available data from the terminated HERO and OLE trials, which were not powered to assess efficacy.
Aardvark Therapeutics, Inc. director Zhongwei Zhang received a grant of stock options covering 127,061 common shares on October 7, 2026. The options vest in 36 equal installments on each monthly anniversary of the grant date and are fully vested on the third anniversary, subject to Zhang's continuous service through each applicable vesting date.
Aardvark Therapeutics, Inc. (AARD) identifies director Zhongwei Zhang as a reporting person in a Form 3 ownership filing.
Aardvark Therapeutics, Inc. appointed David (Zhongwei) Zhang, Ph.D., MBA, as a Class II independent director, effective October 7, 2026. Zhang is Chief Strategy Officer of Abivax and has more than 25 years of experience designing clinical programs, analyzing pivotal-trial data and supporting regulatory submissions, including prior roles at Alumis and MyoKardia.
Under Aardvark’s Non-Employee Director Compensation Program, Zhang is entitled to $40,000 per year in cash, prorated for his service, and received an option on October 7 for a number of shares calculated by dividing $500,000 by the option’s per-share grant-date fair value. The option vests 1/36 on each monthly anniversary, subject to continued service; if a Change in Control occurs during his board service, it vests in full at closing. Aardvark also identified uncertainties related to the FDA clinical hold on ARD-101 and its ongoing engagement with the FDA as risks to forward-looking statements.
Aardvark Therapeutics, Inc. (AARD) reported that its Chief Financial & Operating Officer, Sun Nelson, sold a total of 76,754 shares of common stock in open-market transactions on September 10 and September 11, 2026, at weighted-average prices around $5.00–$5.18 per share.
The filing states these transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2026, indicating they were pre-arranged. A related footnote also notes that the reported holdings include 3,745 shares acquired through Aardvark Therapeutics' 2025 Employee Stock Purchase Plan on May 22, 2026.
Aardvark Therapeutics, Inc. (AARD) received a Rule 144 notice from officer Nelson Sun covering proposed open-market sales of up to 33,911 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ. The shares have an indicated aggregate market value of $169,894.11, compared with 21,884,846 common shares outstanding.
The planned sales include 30,166 shares acquired from previously exercised stock options and 3,745 shares acquired via the Employee Stock Purchase Plan. The notice also reports that Sun, under a Rule 10b5-1 trading plan, sold 14,754 shares for $73,778.18 on September 10, 2026.
Aardvark Therapeutics, Inc. (AARD) is the issuer for a planned resale of restricted securities under Rule 144 by stockholder Nelson Sun. The notice covers 42,843 shares of common stock to be sold through Morgan Stanley Smith Barney, with an indicated aggregate market value of $210,787.56. The shares come from an open market purchase, vested option shares, and shares converted from Series C Preferred stock.
Aardvark Therapeutics, Inc. (AARD) reported that director Jeffrey Chi received a grant of 44,964 stock options on August 14, 2026. The options have an exercise price of $6.54 per share and expire on August 14, 2036. According to the terms, the option vests in full on the earlier of August 14, 2027 or immediately prior to the company’s next Annual Meeting of Stockholders following the grant date, subject to his continuous service through the applicable vesting date.
Aardvark Therapeutics, Inc. (AARD) reported that director Susan E. Graf received a grant of 44,964 stock options to purchase Common Stock. The options have an exercise price of $6.54 per share, expire on August 14, 2036, and were awarded at no purchase price.
The options vest in full on the earlier of August 14, 2027 or immediately before the company’s next Annual Meeting of Stockholders following the grant date, subject to her continuous service through the vesting date. Following this grant, she holds 44,964 options directly.